(Reuters) - Kohl’s (NYSE: KSS) on Friday changed the title of its chief DEI officer and broadened its supplier diversity ...

Over the past six decades, hundreds of millions of people have taken Xanax or one of its relatives in the benzodiazepine family for a range of ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Sponsored by the Indian Council of Social Science Research (ICSSR), the seminar served as a platform for experts, researchers ...

The latest trading day saw Pfizer (PFE) settling at $25.60, representing a -0.43% change from its previous close.

This article has been corrected to reflect that the senators asked UpScriptHealth to respond. In August 2024, Pfizer Inc ...

Summit Therapeutics (NASDAQ: SMMT) has been one of the hottest stocks to own over the past 12 months, with its valuation soaring 300% during that stretch. But things have slowed o ...

Pfizer is ranked third among the best pharma stocks to buy according to hedge funds. The company boasts a strong oncology ...

Guggenheim analyst Vamil Divan maintained a Buy rating on Pfizer (PFE – Research Report) yesterday. The company’s shares closed yesterday at ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Arvinas (ARVN) stock faces a downgrade after underwhelming trial data for breast cancer drug vepdegestrant developed with ...

Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus ...